Suppr超能文献

前瞻性、开放标签、为期18个月的羟基磷灰石钙(瑞得喜)用于人类免疫缺陷病毒相关脂肪萎缩患者面部软组织填充的试验:一年期疗效持久性

Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.

作者信息

Silvers Stacey L, Eviatar Joseph A, Echavez Michael I, Pappas Alexandra L

机构信息

Chelsea Eye and Cosmetic Surgery Associates, New York, NY 10011, USA.

出版信息

Plast Reconstr Surg. 2006 Sep;118(3 Suppl):34S-45S. doi: 10.1097/01.prs.0000234847.36020.52.

Abstract

BACKGROUND

The objective was to evaluate the safety and effectiveness of soft-tissue augmentation of calcium hydroxylapatite (Radiesse) in patients with facial lipoatrophy secondary to human immunodeficiency virus disease.

METHODS

This 18-month, prospective, open-label, multicenter clinical trial of calcium hydroxylapatite for soft-tissue augmentation of patients with facial lipoatrophy enrolled 100 subjects (94 men and six women).

RESULTS

Correction of facial lipoatrophy was evaluated by comparing changes from baseline using the Global Aesthetic Improvement Scale, with confirmation using standardized photography. All 100 patients were determined to be improved or better at 3 months. Secondary effectiveness endpoints-improvement at 6 months on the scale and skin thickness measurements at 3 and 6 months-were also met. Twelve-month data and 18-month scale scores were also available. One hundred percent of assessable patients were rated as improved or better on the scale at every time point through 12 months; 91 percent were improved or better at 18 months. "Yes" responses to all patient satisfaction questions ranged from 97 percent to 100 percent at every evaluation through 12 months. In addition, skin thickness measurements at 12 months remained statistically better than those at baseline. Eighteen-month patient satisfaction and skin thickness measurements were not available at the time of submission. Adverse events reported through 12 months were generally mild (ecchymosis, edema, erythema, pain, and pruritus), not unexpected, and generally short in duration. Eighteen-month safety data were not available at the time of submission.

CONCLUSIONS

Radiesse is an appropriate and well-tolerated treatment for patients with facial lipoatrophy. It demonstrates an excellent safety profile, causes immediate augmentation of the soft tissues, and appears to provide relatively long-lasting improvement in appearance, with very high patient satisfaction.

摘要

背景

目的是评估羟基磷灰石(瑞蓝)软组织填充术对继发于人类免疫缺陷病毒病的面部脂肪萎缩患者的安全性和有效性。

方法

这项为期18个月的前瞻性、开放标签、多中心临床试验,纳入了100名面部脂肪萎缩患者(94名男性和6名女性),使用羟基磷灰石进行软组织填充。

结果

通过使用全球美学改善量表比较与基线相比的变化来评估面部脂肪萎缩的矫正情况,并通过标准化摄影进行确认。所有100例患者在3个月时均被判定有改善或改善更明显。次要有效性终点——6个月时量表上的改善情况以及3个月和6个月时的皮肤厚度测量结果——也均达到标准。还获得了12个月的数据和18个月时的量表评分。在12个月内的每个时间点,100%可评估的患者在量表上被评为有改善或改善更明显;在18个月时,91%的患者有改善或改善更明显。在12个月内的每次评估中,对所有患者满意度问题回答“是”的比例在97%至100%之间。此外,12个月时的皮肤厚度测量结果在统计学上仍优于基线时。在提交报告时,没有18个月时的患者满意度和皮肤厚度测量数据。在12个月内报告的不良事件一般较轻(瘀斑、水肿、红斑、疼痛和瘙痒),并非意外情况,且持续时间一般较短。在提交报告时,没有18个月时的安全性数据。

结论

瑞蓝是对面部脂肪萎缩患者合适且耐受性良好的治疗方法。它显示出极佳的安全性,能立即增加软组织量,并且似乎能使外观得到相对持久的改善,患者满意度非常高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验